H. Eriksson

W. Earley, H. Eriksson, H. Katila, 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.

D. Adson, W. Earley, H. Eriksson, 2011, Journal of affective disorders.

Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study

A. Lazarus, R. Weisler, H. Eriksson, 2009, CNS Spectrums.

Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder

S. Montgomery, H. Svedsäter, H. Eriksson, 2014, International clinical psychopharmacology.

Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline

M. Bauer, E. Vieta, B. Bandelow, 2014, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.

J. Newcomer, H. Eriksson, Peter Zhang, 2019, The Journal of clinical psychiatry.

Content validity of the Sheehan Irritability Scale in patients with major depressive disorder

D. Sheehan, G. Dunbar, D. Revicki, 2016, International clinical psychopharmacology.

Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies

J. Newcomer, E. Weiller, H. Eriksson, 2018, Current medical research and opinion.

Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD

A. Albrechtsen, I. Moltke, Stinus Lindgreen, 2021, Psychiatry Research.

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

M. Fava, E. Weiller, C. Watling, 2017, Neuropsychiatric disease and treatment.

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo‐controlled trial

M. Liebowitz, R. Lam, U. Lepola, 2010, Depression and anxiety.

Effect of Brexpiprazole on Prolactin

H. Eriksson, J. Ivković, M. Hobart, 2018, Journal of clinical psychopharmacology.

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale

H. Eriksson, Peter Zhang, M. Hobart, 2018, The international journal of neuropsychopharmacology.

Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels

A. Altamura, S. Montgomery, H. Eriksson, 2014, International clinical psychopharmacology.

Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study

H. Eriksson, A. Cutler, C. Merideth, 2012, International clinical psychopharmacology.

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.

D. Sheehan, H. Svedsäter, H. Eriksson, 2013, Journal of affective disorders.

Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial

Hans Eriksson, O. Brawman‐Mintzer, M. Katzman, 2011, International clinical psychopharmacology.

Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.

R. McIntyre, M. Bauer, S. Montgomery, 2013, Journal of affective disorders.

Double‐blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder

H. Eriksson, C. Datto, F. She, 2013, International journal of geriatric psychiatry.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy

M. Trivedi, M. Thase, M. Bauer, 2013, International clinical psychopharmacology.

The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia

P. Chue, E. Stip, A. Malla, 2013, Current medical research and opinion.

Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment

M. Thase, K. Demyttenaere, M. Bauer, 2014, International clinical psychopharmacology.

Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.

R. McIntyre, M. Bauer, H. Eriksson, 2013, The international journal of neuropsychopharmacology.

P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects

C. Halldin, L. Farde, A. Jucaite, 2008, European Neuropsychopharmacology.

Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.

M. Trivedi, K. Demyttenaere, B. Bandelow, 2013, The international journal of neuropsychopharmacology.

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

Gang Wang, W. Earley, H. Eriksson, 2012, Neuropsychiatric disease and treatment.

Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.

P. Wahlqvist, H. Eriksson, U. Gustafsson, 2014, Journal of comparative effectiveness research.

Safety and Tolerability of Dexmecamylamine (TC-5214) Adjunct to Ongoing Antidepressant Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy: Results of a Long-Term Study

G. Dunbar, D. Hosford, H. Eriksson, 2015, Journal of clinical psychopharmacology.

Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.

M. Thase, R. Mcquade, W. Carson, 2015, The Journal of clinical psychiatry.

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

C. Correll, J. Ouyang, R. Mcquade, 2015, The American journal of psychiatry.

P.2.g.008 Extended release quetiapine fumarate monotherapy as maintenance treatment in patients with major depressive disorder (MDD)

R. Lam, U. Lepola, H. Eriksson, 2008, European Neuropsychopharmacology.

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy

H. Möller, G. Dunbar, K. Demyttenaere, 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol

M. Hotopf, D. Mohr, R. Dobson, 2019, BMC Psychiatry.